BioMarin Pharmaceutical (1BMRN) Income Statement
BioMarin Pharmaceutical Income Statement
Last quarter (Q2 2026), BioMarin Pharmaceutical's total revenue was $989.71M, an increase of 19.91% from the same quarter last year. In Q2, BioMarin Pharmaceutical's net income was $44.76M. See BioMarin Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 3.22B | $ 2.85B | $ 2.42B | $ 2.10B | $ 1.85B | |
| $ 2.48B | $ 2.27B | $ 1.89B | $ 1.59B | $ 1.38B | |
| $ 1.95B | $ 1.79B | $ 1.70B | $ 1.43B | $ 1.46B | |
| Depreciation and Amortization | $ 79.56M | $ 96.43M | $ 104.39M | $ 101.97M | $ 108.04M |
| $ 572.94M | $ 650.53M | $ 306.77M | $ 265.36M | $ 47.43M | |
| $ 533.48M | $ 484.21M | $ 185.77M | $ 160.97M | $ -82.34M | |
| $ -51.00M | $ 57.55M | $ 2.79M | $ -11.40M | $ 6.99M | |
| $ 482.48M | $ 541.76M | $ 188.56M | $ 149.58M | $ -75.35M | |
| $ 348.90M | $ 426.86M | $ 167.65M | $ 141.56M | $ -64.08M | |
| Per Share Metrics | |||||
| Basic EPS | $ 1.82 | $ 2.25 | $ 0.89 | $ 0.76 | $ -0.35 |
| Diluted EPS | $ 1.80 | $ 2.21 | $ 0.88 | $ 0.75 | $ -0.35 |
| Weighted Average Shares Outstanding | 191.79M | 190.03M | 187.83M | 185.27M | 182.85M |
| Weighted Average Shares Outstanding (Diluted) | 197.39M | 196.71M | 191.59M | 188.96M | 182.85M |
Currency in USD
